{"id":1329,"date":"2026-01-19T11:34:53","date_gmt":"2026-01-19T11:34:53","guid":{"rendered":"https:\/\/www.arcgroup.io\/uxbridge\/?p=1329"},"modified":"2026-01-19T11:39:34","modified_gmt":"2026-01-19T11:39:34","slug":"amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/","title":{"rendered":"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_995ae99eab505b16cafef0f50d71fa4f\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-300x207.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-1024x706.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-768x530.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-1000x690.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p>Amgen&nbsp;has announced its acquisition of&nbsp;Dark Blue Therapeutics Ltd., a privately held biotechnology company based in Oxford,&nbsp;advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to&nbsp;$840 million. &nbsp;<\/p>\n\n\n\n<p>The acquisition adds to\u00a0Amgen&#8217;s portfolio an investigational small molecule that targets and degrades two proteins (MLLT1\/3) that drive specific types of acute myeloid leukemia (AML), a fast-growing blood cancer. Preclinical data in leukemia models demonstrate promising anti-cancer activity and mechanistic differentiation from currently available therapies, establishing the rationale for single-agent and combination use to overcome treatment resistance and enhance durability of remission.<\/p>\n\n\n\n<p>&#8220;Acute myeloid leukemia remains one of the most difficult cancers to treat, and we see an urgent need for new mechanisms capable of changing the trajectory of this disease,&#8221; said\u00a0<strong>Jay Bradner, M.D., executive vice president of\u00a0Research and Development\u00a0at\u00a0Amgen<\/strong>. &#8220;This acquisition complements and extends our research in targeted protein degradation and leukemia therapeutics, advancing our strategy to invest early in rising medicines for novel therapeutic targets. The adjacency of this program to our considered expertise in cancer biology will propel MLLT1\/3-targeting medicines to clinical investigation for patients facing the challenging diagnosis of AML.&#8221;<\/p>\n\n\n\n<p>Amgen&nbsp;expects to integrate&nbsp;Dark Blue Therapeutics&nbsp;into its existing research organisation, further strengthening the company&#8217;s early oncology discovery efforts.<\/p>\n\n\n\n<p>Amgen has a UK base at ARC Uxbridge where it hosts its UK Development Centre and sits as part of ARC Uxbridge\u2019s pharma cluster with pharma and biotech firms including &nbsp;Bristol Myers Squibb, Norgine and Daiichi Sankyo.<\/p>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n    <section class=\"news-archive \" id=\"block_7b734e3288b8e5ab2f815c13d5e0fe8e\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/07\/11\/arc-uxbridge-named-workspace-of-the-year-at-the-2025-hustle-awards\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-300x200.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-1024x683.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-768x512.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-1000x667.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/07\/11\/arc-uxbridge-named-workspace-of-the-year-at-the-2025-hustle-awards\/\" target=\"_self\">\n\t\t\t\tARC Uxbridge, named Workspace of the Year at the 2025 Hustle Awards\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/03\/25\/arc-uxbridge-outperforms-5-year-average-uptake-for-the-area\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-300x200.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-768x512.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/03\/25\/arc-uxbridge-outperforms-5-year-average-uptake-for-the-area\/\" target=\"_self\">\n\t\t\t\tBrookfield&#8217;s ARC Uxbridge Campus Outperforms 5-year average uptake for the area following surge in high-profile leases\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/12\/17\/byd-arc-uxbridge\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/12\/Building-05-credit-Murray-Scott-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/12\/Building-05-credit-Murray-Scott-300x201.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/12\/Building-05-credit-Murray-Scott-1024x687.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/12\/Building-05-credit-Murray-Scott-768x515.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/12\/Building-05-credit-Murray-Scott-1000x671.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/12\/Building-05-credit-Murray-Scott-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/12\/17\/byd-arc-uxbridge\/\" target=\"_self\">\n\t\t\t\tThe Next Stop is ARC Uxbridge for BYD\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>Amgen&nbsp;has announced its acquisition of&nbsp;Dark Blue Therapeutics Ltd., a privately held biotechnology company based in Oxford,&nbsp;advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to&nbsp;$840 million. &nbsp; The acquisition adds to\u00a0Amgen&#8217;s portfolio an investigational small molecule that targets and degrades two proteins (MLLT1\/3) that drive specific types of acute myeloid [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":1235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[4277],"class_list":["post-1329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-science-and-technology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - ARC Uxbridge<\/title>\n<meta name=\"description\" content=\"Amgen acquires\u00a0Dark Blue Therapeutics Ltd., a privately held biotech company based in Oxford,\u00a0in a transaction valued at up to\u00a0$840 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - ARC Uxbridge\" \/>\n<meta property=\"og:description\" content=\"Amgen acquires\u00a0Dark Blue Therapeutics Ltd., a privately held biotech company based in Oxford,\u00a0in a transaction valued at up to\u00a0$840 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Uxbridge\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T11:34:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T11:39:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1765\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"nataliegelder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nataliegelder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\"},\"author\":{\"name\":\"nataliegelder\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\"},\"headline\":\"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline\",\"datePublished\":\"2026-01-19T11:34:53+00:00\",\"dateModified\":\"2026-01-19T11:39:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\",\"keywords\":[\"Science and technology\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\",\"name\":\"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - ARC Uxbridge\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\",\"datePublished\":\"2026-01-19T11:34:53+00:00\",\"dateModified\":\"2026-01-19T11:39:34+00:00\",\"description\":\"Amgen acquires\u00a0Dark Blue Therapeutics Ltd., a privately held biotech company based in Oxford,\u00a0in a transaction valued at up to\u00a0$840 million.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\",\"width\":2560,\"height\":1765},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/uxbridge\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/\",\"name\":\"ARC Uxbridge\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\"},\"alternateName\":\"ARC Uxbridge\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/uxbridge\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\",\"name\":\"ARC Uxbridge\",\"alternateName\":\"ARC Uxbridge\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png\",\"width\":2084,\"height\":2085,\"caption\":\"ARC Uxbridge\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\",\"name\":\"nataliegelder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"caption\":\"nataliegelder\"},\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/author\/nataliegelder\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - ARC Uxbridge","description":"Amgen acquires\u00a0Dark Blue Therapeutics Ltd., a privately held biotech company based in Oxford,\u00a0in a transaction valued at up to\u00a0$840 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - ARC Uxbridge","og_description":"Amgen acquires\u00a0Dark Blue Therapeutics Ltd., a privately held biotech company based in Oxford,\u00a0in a transaction valued at up to\u00a0$840 million.","og_url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/","og_site_name":"ARC Uxbridge","article_published_time":"2026-01-19T11:34:53+00:00","article_modified_time":"2026-01-19T11:39:34+00:00","og_image":[{"width":2560,"height":1765,"url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg","type":"image\/jpeg"}],"author":"nataliegelder","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nataliegelder","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/"},"author":{"name":"nataliegelder","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3"},"headline":"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline","datePublished":"2026-01-19T11:34:53+00:00","dateModified":"2026-01-19T11:39:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg","keywords":["Science and technology"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/","url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/","name":"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - ARC Uxbridge","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg","datePublished":"2026-01-19T11:34:53+00:00","dateModified":"2026-01-19T11:39:34+00:00","description":"Amgen acquires\u00a0Dark Blue Therapeutics Ltd., a privately held biotech company based in Oxford,\u00a0in a transaction valued at up to\u00a0$840 million.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#primaryimage","url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg","contentUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg","width":2560,"height":1765},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/uxbridge\/"},{"@type":"ListItem","position":2,"name":"Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#website","url":"https:\/\/www.arcgroup.io\/uxbridge\/","name":"ARC Uxbridge","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization"},"alternateName":"ARC Uxbridge","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/uxbridge\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization","name":"ARC Uxbridge","alternateName":"ARC Uxbridge","url":"https:\/\/www.arcgroup.io\/uxbridge\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png","contentUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png","width":2084,"height":2085,"caption":"ARC Uxbridge"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3","name":"nataliegelder","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","caption":"nataliegelder"},"url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/author\/nataliegelder\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts\/1329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/comments?post=1329"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts\/1329\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/media\/1235"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/media?parent=1329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/categories?post=1329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/tags?post=1329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}